Earnings History of Immune Pharmaceuticals, Inc. (NASDAQ:IMNP)

stock updates

Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) moved down -4.87% and closed its last trading session at $0.21. This Medical Sector stock currently has the Market Capitalization of 22.81 Million. The Average Volume for the stock is measured as 3.22 Million. The Stock has a 52-Week High of $1.54 and 52-Week Low of $0.2 following the dates, it touched its 52-Week High on Nov 9, 2015 and 52-Week Low on Oct 21, 2016. Currently, the Return on Assets value for the trailing twelve months is -83.1% with the Return on Equity and Return on Investment of -389.6% and 0% respectively. This firm currently has YTD (year to date) performance of -70.81 Percent which is not good. The Short Ratio for the stock is 1.33.

Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) Price to Earnings (P/E) ratio is 0. EPS or Earning per Share stands at $-0.92. The TTM operating margin is 0 percent.

Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) is due to report its Earnings on Thu 10 Nov (In 18 Days). The estimated EPS for the current quarter is said to be $-0.14. Following Earnings result, share price were DOWN 4 times out of last 5 Qtrs. The stock has reduced about -48.8% since it reported its last earnings. The Closing price of Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) at Last Earnings was $0.41 as compared to the previous closing price of $0.22. The Predicted Move on the 7th day after Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) will release its earnings at about 11%.

By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) beats earnings by 33%, The Stock Missed Earnings  6  times and has met earnings  1 times.

Earnings History:

We will discuss the past Quarters Earnings below:

Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) reported its previous quarter on 08/15/2016 where it reported the Actual Earnings of $-0.13. The Closing price before the company posted its earnings was $0.41. The Stock declined on the very next day of earnings and maintained its stock price at $0.39 by showing a % change of -4.88 percent from its previous closing price. The Next Day Volume after Earnings was reported as 3.2 Million. On the 7th day After Earnings Report, the stock hit its share price as $0.38 by showing -7.32% decrease from the Stock price Before Earnings were reported.

On 05/16/2016, the stock reported the EPS of $-0.17 where Analysts were projecting the EPS to be $-0.15 showing a difference of $-0.02. Thus Surprise Factor was there with -13.3 percent. Before Earnings Announcement on 05/16/2016, the firm had its stock price of $0.27. And immediately on the next day after earnings announcement, the stock inclined 11.11% and closed its trading session at $0.3. On 7th Day after earnings release, Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) surged to 0% from $0.27 to $0.27.

On Next Day, Analysts were suspecting EPS of $-0.14/share where Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) reported its Actual EPS of $-0.27. Thus showing a Surprise of -92.9 percent. The Closing Price of the stock before earnings was $0.108 while on the Next day the stock closed its trading session at $-0.0488 with a percentage change of 20% from the price of 0.108 before Earnings. The Stock Closing Price on the 7th day of earnings was $1. Earning Dates Reminder.

Company Profile:

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas. The company’s lead product candidate is Bertilimumab, a human monoclonal antibody, which is in Phase II clinical trial for the treatment of ulcerative colitis, bullous pemphigoid, and Crohn’s disease. It is also developing NanoCyclo, a topical nanocapsule formulation of cyclosporine, for the treatment of psoriasis and atopic dermatitis; Ceplene, a small molecule, which has completed Phase III clinical trials targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies; Azixa, a Phase II clinical trial novel microtubular destabilizer that functions as a vascular disruption agent; and Crolibulin, a novel small molecule vascular disruption agent and apoptosis inducer, which is in Phase II clinical trials for the treatment of patients with solid tumors. The company’s products also include NanomAbs technology platform, an antibody-drug conjugate platform for the treatment of cancer; novel technology platform for the construction of bispecific antibodies for immunotherapies; and AmiKet, a prescription topical analgesic cream, which is in Phase III clinical trial to treat peripheral neuropathies. It has license, and other collaborative research and development arrangements with BioNanoSim Ltd.; Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.; Atlante Biotech SAS; Shire Biochem, Inc.; Lonza Sales AG; MabLife SAS; iCo Therapeutics Inc.; Dalhousie University; and Endo Pharmaceuticals Inc. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in New York, New York.